Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males

Psychiatry Research

Volumn 167, Issue 1-2, 2009, Pages 73-79

  Ovaskainen, Yrjö ^a   Koponen, Hannu ^b,c   Jokelainen, Jari ^d,e   Keinänen Kiukaanniemi, Sirkka ^d,e,f   Kumpusalo, Esko ^c,g   Vanhala, Mauno ^h,i  

^a Moisio Hospital   (Finland)

^b ACADEMY OF FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f Oulu Health Center   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h Laukaa Health Center   (Finland)

ⁱ Central Finland Central Hospital   (Finland)

Author keywords

Beck Depression Inventory; Cytokines; Depression; Interleukin 1 beta; Interleukin 1 receptor antagonist; Metabolic syndrome; Overweight

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYMPTOMATOLOGY;

DEPRESSIVE DISORDER; FEMALE; FINLAND; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PERSONALITY INVENTORY; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 64649106914     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2007.12.004     Document Type: Article

References (32)

1. Alesci S., Martinez P.E., Kelkar S., Ilias I., Ronsaville D.S., Listwak S.J., Ayala A.R., Licinio J., Gold H.K., Kling M.A., Chrousos G.P., and Gold P.W. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: Clinical implications. The Journal of Clinical Endocrinology & Metabolism 90 (2005) 2522-2530
2. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 4 (1961) 561-571
3. Beratis S., Katrivanou A., Georgiou S., Monastirli A., Pasmatzi E., Gouris P., and Tsambalos D. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-α treatment. Journal of Psychosomatic Research 58 (2005) 15-18
4. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circulation Research 95 (2004) 858-866
5. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. The New England Journal of Medicine 354 (2006) 610-621
6. Dunn A.J., Swiergiel A.H., and de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neuroscience and Biobehavioral Reviews 29 (2005) 891-909
7. Ferketich A.K., Ferguson J.P., and Binkley P.F. Depressive symptoms and inflammation among heart failure patients. American Heart Journal 150 (2005) 132-136
8. Furlanetto L.M., Mendlowicz M.V., and Bueno J.R. The validity of the Beck Depression Inventory-Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. Journal of Affective Disorders 86 (2005) 87-91
9. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National heart, lung, and blood institute scientific statement: executive summary. Circulation 112 (2005) e285-e290
10. Kenis K., and Maes M. Effects of antidepressants on the production of cytokines. International Journal of Neuropsychopharmacology 5 (2002) 401-412
11. Kaestner F., Hetich M., Peters M., Sibrowki W., Hetzel G., Ponath G., Arolt V., Cassens U., and Rothermundt M. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic depression are associated with HPA axis activity. Journal of Affective Disorders 87 (2005) 305-311
12. Kim, Y.K., Na, K.S., Shin, K.H., Jung, H.Y., Choi, S.H., Kim, J.B., 2007. Cytokine imbalance in the pathophysiology of major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1044-1053.
13. Lasa L., Ayuso-Mateos J.L., Vazquez-Barquero J.L., Diez-Manrique J.F., and Dowrick C.F. The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. Journal of Affective Disorders 57 (2000) 261-265
14. Leonard B.E. The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25 (2001) 767-780
15. Loddick S.A., Wong M.L., Bongiorno P.B., and Gold P.W. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochemical and Biophysiological Research Communications 234 (1997) 211-215
16. Maes M., Vandoolaeghe E., Ranjan R., Bosmans E., Bergmans R., and Desnyder R. Increased serum interleukin-1-receptor-antagonist in major depression. Journal of Affective Disorders 36 (1995) 29-36
17. Maes M., Bosmans E., De Jogh R., Kenis G., Vandoolaeghe E., and Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9 (1997) 853-858
18. Marques-Deak A.H., Neto F.L., Dominguez W.V., Solis A.C., Kurcgant D., Sato F., Ross J.M., and Prado E.B.A. Cytokine profiles in women with different subtypes of major depressive disorder. Journal of Psychiatric Research 41 (2007) 152-159
19. Owen B.M., Eccleston D., Ferrier I.N., and Young A.H. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatrica Scandinavica 103 (2001) 226-228
20. Pariante C.M., and Miller A.H. Glucocorticoid receptor in major depression: relevance to the pathophysiology and treatment. Biological Psychiatry 49 (2001) 391-404
21. Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A., and Kirchner H. Inflammatory markers in major depression and melancholia. Journal of Affective Disorders 63 (2001) 93-102
22. Salmenniemi U., Ruotsalainen E., Pihlajamäki J., Vauhkonen I., Kainulainen S., Punnonen K., Vanninen E., and Laakso M. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110 (2004) 3842-3848
23. Schiepers O.J.G., Wichers M.C., and Maes M. Cytokines and major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29 (2005) 201-217
24. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Current Medical Research Opinion 20 (2004) 295-304
25. Spranger J., Kroke A., Möhlig M., Hoffman K., Bergmann M.M., Ristow M., Boeing H., and Pfeiffer A.F.H. Inflammatory cytokines and the risk to develop type 2 diabetes. Results from the prospective population-based European prospective investigation into cancer and nutrition (EPIC-) Potsdam study. Diabetes 52 (2003) 812-817
26. Steer R.A., Ball R., Ranieri W.F., and Beck A.T. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. Journal of Clinical Psychology 55 (1999) 117-128
27. Suarez E.C., Krishnan R.R., and Lewis J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosomatic Medicine 65 (2003) 362-368
28. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., and O'Brien J.T. Increase in interleukin-1(beta) in late-life depression. American Journal of Psychiatry 162 (2005) 175-177
29. Vanhala P., Vanhala M., Kumpusalo E., and Keinänen-Kiukaanniemi S. The quantitative insulin sensitivity check index QUICKI predicts the onset of type 2 diabetes better than fasting plasma insulin in obese subjects; a 5-year follow-up study. Journal of Clinical Endocrinology and Metabolism 87 (2002) 5834-5837
30. Wichers M., and Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology 5 (2002) 375-388
31. Wichers M.C., Kenis G., Leue C., Koek G., Robaeys G., and Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biological Psychiatry 60 (2006) 77-79
32. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., and Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. Journal of Psychosomatic Research 62 (2007) 207-214